Aspirin is a commonly used drug with a wide pharmacological spectrum including antiplatelet, anti-inflammatory, and neuroprotective actions. This study shows that aspirin and sodium salicylate, its major blood metabolite, reverse contractile actions of endothelin-1 (ET-1) in isolated rat aorta and human mammary arteries. They also prevent the intracellular Ca The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of salicylates and ETA receptor antagonists should be used to evaluate the physiopathological role of ET-1 and may be of therapeutic interest in the treatment of ischemic heart disease.
I-ET-1 to ETA receptors. Salicylates do not promote dissociation of 125 I-ET-1 ETB receptor complexes. Salicylates potentiate relaxing actions of receptor antagonists such as bosentan. It is concluded that salicylates are allosteric inhibitors of ETA receptors. The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of salicylates and ETA receptor antagonists should be used to evaluate the physiopathological role of ET-1 and may be of therapeutic interest in the treatment of ischemic heart disease.
Aspirin (acetylsalicylic acid) has antiplatelet, anti-inflammatory, and neuroprotective actions, but its molecular mechanisms of action are complex. Aspirin was reported two decades ago to inhibit platelet cyclooxygenase activity and the formation of thromboxanes (Patrono, 1994) . A growing number of studies suggest, however, that anti-inflammatory actions of aspirin may not be related to the inhibition of prostaglandin synthesis. For instance, salicylates activate p38 mitogen-activated protein kinase and inhibit tumor necrosis factor-induced IB phosphorylation (Schwenger et al., 1997 (Schwenger et al., , 1998 .
A major clinical use of aspirin therapy is to improve the survival of patients with myocardial infarction and unstable angina (ISIS-2, 1988 ). This action is usually attributed to the antiplatelet action of aspirin, but participation of other mechanisms of action cannot be excluded. For instance, aspirin has recently been shown to protect endothelial cells against oxidative stresses, possibly by promoting the synthesis of ferritin (Oberle et al., 1998) .
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide (Yanagisawa et al., 1988) that plays an important role in several diseases thought to be associated with vasoconstrictions. These are coronary vasospasm (Toyo-oka et al., 1991) , unstable angina (Weiczorek et al., 1994) , myocardial infarction (Omland et al., 1994) , cardiac insufficiency (Mulder et al., 1997) , and cerebral vasospasm associated with subarachnoid hemorrhage (Clozel et al., 1993) . The fact that protective actions of aspirin are observed in conditions that are associated to increased circulating levels of ET-1 suggested to us that aspirin may have anti-ET-1 properties. This study was designed to test this hypothesis. It shows that salicylates are allosteric inhibitors of ETA receptors. receptors were prepared as described previously . Cell homogenates were prepared as described previously (Desmarets et al., 1996) and stored at Ϫ20°C. Proteins were determined according to Bradford (1976) using BSA as standard. Receptor densities were 0.4 Ϯ 0.1 pmol/mg of proteins in membranes prepared from B7 cells (Vigne et al., 1990) . They were 26 Ϯ 1 and 4 Ϯ 0.5 pmol/mg in membranes prepared from ETA and ETB receptor-expressing fibroblasts, respectively.
Contraction Experiments. Thoracic aorta from 200-g female Wistar rats were cleaned of adherent fat, cut into rings, and the endothelium was removed. Human internal mammary arteries from seven patients (six men and one woman, age 56-83, mean 63.5 Ϯ 4.3 years) undergoing bypass surgery were collected. All the procedures followed were in accordance with institutional guidelines. In the operating room, fragments were immediately placed in a Krebs' solution buffered at pH 7.4 with 25 mM HEPES/NaOH. Fragments were cleaned of adherent connective tissues. The endothelium was removed by gently rubbing the intimal surface with the tips of small forceps and 3-to 4-mm wide rings were prepared.
Rings were mounted under 2 g resting tension in organ baths (3 ml, 37°C, bubbled with a 5% CO 2 and 95% O 2 gas mixture) containing Krebs bicarbonate solution of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4Ј , 25 mM NaHCO 3 , 2 mM CaCl 2 , and 5.8 mM glucose; pH 7.4. After a 60-min period of equilibration during which the buffer was changed at 15-min intervals, four contraction/relaxation cycles were performed using 40 mM KCl. Rings were then exposed to ET-1, and salicylates and changes in tension were monitored on a Gould TA4000 recorder. All experiments using human mammary arteries were performed in the presence of 10 M indomethacin to inhibit cyclooxygenase.
Binding Experiments. All experiments were performed at 20°C. Cell homogenates (10 g of protein/ml) were incubated in the presence of 4 to 20 pM 125 I-ET-1 and effectors in an Earle's salt solution supplemented with a cocktail of protease inhibitors (0.1 mM bacitracin, 0.1 mM phenylmethylsulfonyl fluoride, 1 M leupeptin). After selected times of incubation, aliquots of the incubation solution were filtered under reduced pressure onto Sartorius 0.2-m filters and washed three times with 4 ml of 0.1 M MgCl 2 . Filters were then counted. Nonspecific binding was measured in parallel experiments using 100 nM unlabeled ET-1. Equilibrium binding experiments and dissociation experiments were performed after 3 h of equilibration of receptors with 125 I-ET-1. Triplicate experiments were performed. Intracellular Ca 2؉ Measurements. For intracellular Ca 2ϩ measurements, suspended endothelial cells were incubated for 30 min in the presence of 5 M indo-1/AM, centrifuged at 1000g, and resuspended into an Earle's salt solution at a density of 10 6 cells/ml. ET-1, neuromedin B, or UTP was added to the cell suspension. After mild vortexing, tubes were inserted into a FacStar Plus cytometer (Becton Dickinson) (Vigne et al., 1994) . Mean fluorescence ratios were determined for 1000 cells sampled between 8 and 10 s after the addition of agonists. This time corresponded to the peak of the intracellular Ca 2ϩ transients. Fluorescence ratios were calculated in arbitrary units set to a value of 100 for unstimulated cells.
Nonreactivity of ET-1 and SA. It was important to define whether SA interacted and modified ET-1. ET-1 (4 nmol) was added to an Earle's salt solution supplemented with 20 mM SA. After 75 min of equilibration at room temperature, the mixture was injected on a C18 Lichrocart 250-4 HPLC column (Merck, Darmstadt, Germany). The column was eluted for 60 min at a rate of 1 ml/min with a linear 10 to 50% acetonitrile gradient in the presence of 0.1% trifluoroacetic acid. No evidence for a change in the retention time of ET-1 (49 min) or for a degradation of ET-1 could be obtained.
In another series of experiments, 125 I-ET-1 (150 pM) was incubated with membranes (0.5 g/ml) and ligand receptor complexes were allowed to form for 3 h at room temperature. Complexes were then separated from the free ligand by filtration onto Sartorius filters. After extensive washing of the filters with 0.1 M MgCl 2 , filters were incubated in 1.5 ml of Earle's salt solution supplemented with 20 mM SA to induce dissociation of preformed complexes. After 100 min at room temperature, an aliquot of the supernatant (40,000 dpm) was injected on a C18 column under the conditions described above. Fractions were collected and counted. Most of the label (87%) eluted as a single peak that had the same retention time as 125 I-ET-1. The remaining label eluted in the void volume. Taken together, these results indicated that SA did not induce a degradation of 125 I-ET-1 either in a free form or in a receptor-bound form. Data Presentation and Statistical Analysis. Data are given as mean Ϯ S.E. and the number of experiments performed. Statistical analysis was performed with the paired t test. Values of P Ͻ .05 were considered statistically significant. Binding data were analyzed using the Ligand software (Jandel Scientifics, Corte Madera, CA). When no error bar is present on a figure, it was smaller than the size of the points.
Results

Anti-ET-1 Actions of Salicylates on Rat Aortic Rings.
ET-1 induced large and irreversible contractions of isolated rat aortic rings. These contractions are mediated by ETA receptors (Marsault et al., 1991) . Figure 1 presents typical recordings that show that addition of aspirin (Fig. 1A) or SA (Fig. 1B) to arteries that had been precontracted with ET-1 induced rapid and partial relaxations. Data obtained are summarized in Fig. 1, C and D. Figure 1C shows that the half-time for salicylate induced relaxations was independent of the concentration used. The overall half-time of relaxations induced by SA was 2.9 Ϯ 0.6 min (n ϭ 22). The overall half-time of relaxations induced by aspirin was 3.4 Ϯ 0.4 min (n ϭ 21). Figure 1D shows a dose-dependent increase in the maximum extent of the relaxations induced both by aspirin and SA.
Cumulative dose-response curves for the action of ET-1 were established in the absence and the presence of SA. Figure 2 shows that SA shifted the dose-response curves for the actions of ET-1 to larger concentrations. These suggested a competitive type of inhibition. Indomethacin (10 M) did not alter the ET-1 dose-response curve. Identical relaxing actions of salicylates were observed in intact aortic rings and in endothelium-denuded rings (not shown).
Relaxing actions of salicylates were different from those of bosentan, an endothelin receptor antagonist (Clozel et al., 1993) . Application of bosentan to arteries that had been precontracted with 100 nM ET-1 induced slow and almost complete relaxations. Maximum relaxations observed after 90 min of exposure to 10 M bosentan were 90 Ϯ 3% (n ϭ 5). The half-time of relaxations induced by bosentan was 38 Ϯ 4 min (n ϭ 5). It was 10 times longer than that observed for salicylates.
Anti-ET-1 Actions of Salicylates on Human Mammary Arteries. Similar experiments were performed using rings of human internal mammary arteries. This preparation has already been reported to respond to ET-1 by large and sustained contractions that are mainly due to ETA receptors (Seo et al., 1994; Maguire and Davenport, 1995) . Experiments were performed using endothelium-denuded arteries and in the presence of 10 M indomethacin to prevent a possible action of aspirin on cyclooxygenase. Figure 3 shows that SA and aspirin relaxed arteries that had been precontracted with ET-1. The time courses of the relaxations were very similar to those observed with rat aortic rings. Figure  3C also shows cumulative dose-response curves for the ac- Salicylates Prevented ETA Receptor-Mediated Intracellular Ca 2؉ Mobilization. We next looked for anti-ET-1 actions of salicylates at a cellular level. Endothelial cells from brain capillaries were chosen for different reasons: 1) unlike endothelial cells from large peripheral vessels, they express ETA receptors (Vigne et al., 1990) ; 2) they express two other phospholipase C-coupled heptahelical receptors: neuromedin B-preferring bombesin receptors (Vigne et al., 1995) and P2Y 2 purinergic receptors ; and 3) pharmacological properties of receptors can be conveniently monitored by flow cytometric analyses of indo-1-loaded cells (Vigne et al., 1990) . Figure 4A shows that SA and aspirin decreased the ET-1 induced [Ca 2ϩ ]i rise in indo-1-loaded cells. Half maximum inhibition was observed at 2 mM SA and 3 mM aspirin.
The dose-response curve for ET-1 induced [Ca 2ϩ ]i rise is shown in Fig. 4B . Half maximum increase in [Ca 2ϩ ]i was observed at 20 nM ET-1. SA shifted the ET-1 dose-response curve to larger concentrations. Application of the ChengPrusof relationship indicated an apparent K i value for SA of 7 mM.
A concentration of SA of 10 mM that inhibited 80% of ET-1 induced [Ca 2ϩ ]i increases did not modify the Ca 2ϩ mobilizing actions of 1 M neuromedin B that were mediated by neuromedin B preferring bombesin receptors. It did not modify the Ca 2ϩ mobilizing actions of 10 M UTP that were mediated by P2Y2 purinergic receptors. These indicated that actions of SA were specific for ETA receptor. These results also ruled out a possible nonspecific action of SA on the Ca 2ϩ signaling cascade.
Salicylates Inhibited ET-1 Binding to Recombinant ETA Receptors. To further analyze the mechanism of action of salicylates, we performed binding experiments using 125 I-ET-1 and recombinant rat ETA receptors. Figure 5 shows that salicylates prevented 125 I-ET-1 binding. Half maximum inhibition was observed at 10 mM aspirin or SA. Bosentan was much more potent.
Salicylates Modified the Properties of Interaction of ET-1 with ETA Receptors. We next analyzed the kinetics of association of 125 I-ET-1 to ETA receptors and the kinetics of dissociation of the complexes in the presence of different concentrations of SA. Results are shown in Fig. 6 . Association of 125 I-ET-1 to ETA receptors in the absence of SA did not follow pseudo first order kinetics for reasons that have been described previously (Desmarets et al., 1996) . We observed, however, that association kinetics in the presence of SA could be linearized according to pseudo first order processes. Table  1 shows that increasing doses of SA did not modify the second order rate constant of association of 125 I-ET-1 to its receptors. Dissociation kinetics in the absence or the presence of SA were monoexponential. The half-life of 125 I-ET-1 ETA receptor complexes was 12.4 Ϯ 0.5 h (n ϭ 11) in the absence of SA, meaning an almost irreversible binding. SA increased up to 10-fold the rate constant of dissociation of 125 I-ET-1 receptor complexes ( Table 1 ). The apparent equilibrium dissociation constant (K d ) of ET-1 ETA receptor complexes was estimated to be 1.4 pM in the absence of SA. It increased to 12 pM in the presence of 50 mM SA. A Schild plot of the data indicated an apparent K i value for SA of 8 mM. Thus SA decreased the apparent affinity of ET-1 for ETA receptors by favoring dissociation of ET-1 receptor complexes.
In a second series of experiments, 125 I-ET-1 ETA receptor complexes were allowed to form in the absence of SA. Figure  7 shows that addition of SA, in the absence of unlabeled ET-1, induced a partial dissociation of the complexes. Increasing doses of SA increased the fraction of dissociable sites in a manner that was strikingly similar to the pattern of SA-induced relaxations (Fig. 1) .
To further ascertain that the apparent decreases in affinity of ET-1 for its receptors induced by SA quantitatively accounted for the lower 125 I-ET-1 bindings observed in Figs. 6A and 7 we used the K d values listed in Table 1 to calculate the expected effect of SA on equilibrium 125 I-ET-1 binding. Table  2 shows that there was a close agreement between expected and observed decreases in 125 I-ET-1 and ETB receptors also form tight complexes that hardly dissociate. Figure 8 shows that large concentrations of aspirin and SA (50 mM) that accelerated 10 times the dissociation of 125 I-ET-1 ETA receptor complexes (Table 1) , did not induce dissociation of 125 I-ET-1 ETB receptor complexes. Thus, allosteric actions of salicylates are specific for ETA receptors.
We also checked that acetic acid and Na benzoate, which are the component parts of aspirin and SA, at a concentration of 30 mM had no action on the dissociation of 125 I-ET-1 ETA receptor complexes (data not shown). Finally we checked that SA (20 mM) did not induce a degradation of free or receptorbound 125 I-ET-1. Salicylates Potentiated Actions of Receptor Antagonists. The major interest of an allosteric inhibitor of ETA receptors is that it transforms an almost irreversible ET-1 binding into a reversible process. One consequence is that salicylates should favor replacement of bound ET-1 by receptor antagonist and thus potentiate actions of receptor antagonists. This hypothesis was tested using binding experiments and contraction experiments.
125 I-ET-1 ETA receptor complexes were allowed to form in the absence of salicylates. Addition of unlabeled ET-1 induced a decrease in the bound radioactivity, which indicated that 125 I-ET-1 dissociated slowly from the receptors and was replaced by unlabeled ET-1. This type of experiment is in fact used to analyze dissociation kinetics of receptor ligand complexes. Figure 9A shows that addition of 20 mM SA induced a much faster replacement of bound 125 I-ET-1 by unlabeled ET-1. Aspirin was as potent as SA. We next used bosentan instead of unlabeled ET-1. Figure 9B shows that addition of 10 M bosentan to 125 I-ET-1 receptor complexes induced a small decrease of the bound radioactivity. The half-life of 125 I-ET-1 receptor complexes determined in the presence of bosentan was 11.4 Ϯ 1.0 h (n ϭ 3). Identical values were obtained in experiments using unlabeled ET-1 (12.4 Ϯ 0.5 h) or mixtures of 100 nM ET-1 and 10 M bosentan (10.6 Ϯ 0.9 h, n ϭ 3). These indicated that bosentan is not an allosteric inhibitor of ETA receptors. Finally, Fig. 9B shows that SA (20 mM) accelerated the dissociation of 125 I-ET-1 receptor complexes in the presence of bosentan, meaning that SA . Two aortic rings from the same rat were mounted in two parallel organ chambers. One ring served as a control. The other was treated with 10 or 30 mM SA. The two rings were then exposed to increasing doses of ET-1 (1, 3, 10, 30, and 100 nM) and changes in tension were recorded. Mean Ϯ S.E. (n ϭ 12 in A, n ϭ 4 in B) are indicated. **P Ͻ .01, *P Ͻ .05 using a paired t test. Tensions were normalized to that produced by the last KCl contraction. Fig. 3 . Anti-ET-1 actions of salicylates in isolated human mammary arteries. A, representative traces showing relaxing actions of 30 mM SA and 30 mM aspirin on endothelium-denuded rings of mammary arteries. Horizontal bar: 2 min, vertical bar: 0.6 g. C, cumulative ET-1 doseresponse curves in the absence (E) or the presence (F) of 10 mM SA. Experiments were performed as described in the legend of Fig. 2 . Mean Ϯ S.E. (n ϭ 5) are indicated. **P Ͻ .01, *P Ͻ .05 using a paired t test. Tensions were expressed relative to that observed in response to 100 nM ET-1 in the control ring. facilitated replacement of bound ET-1 by bosentan. It is of interest to note that less than 10% of 125 I-ET-1 receptor complexes dissociated after a 4-h exposure to bosentan. About 70% of the complexes dissociated during the same time in the presence of bosentan and SA.
We next tested whether SA promoted the relaxing action of bosentan. SA (10 mM) by itself induced a 38 Ϯ 3% (n ϭ 9) relaxation of ET-1 (100 nM)-contracted aortic rings. Bosentan (10 M) by itself induced a 90 Ϯ 3% relaxation after 90 min. Figure 10A shows that addition of 10 mM SA after bosentan induced a rapid and almost complete relaxation of the arteries. Conversely, addition of bosentan to arteries that had been partially relaxed by 10 mM SA induced fast and complete relaxations (Fig. 10B) . The half-time for the relaxations induced by bosentan was 12.2 Ϯ 0.7 min (n ϭ 13). It was 3 times less than the corresponding time observed in the absence of SA (38 Ϯ 4 min). Thus SA accelerated relaxing actions of bosentan 3-fold.
Discussion
Why Is It Important to Relieve Irreversible ET-1 Binding? Quasi-irreversible ET-1 binding was recognized very early but its consequences are not yet fully understood. Waggoner et al. (1992) first described that the slow rate of dissociation of ET-1 receptor complexes implies K d values of ET-1 receptor complexes in the pM range. We also showed that equilibrium binding studies can greatly underestimate affinity constants for both ET-1 and competing ligands unless special care is not taken to avoid time-limited second order kinetic conditions (Desmarets et al., 1996) . Irreversible binding is responsible for atypical pharmacological responses such as the lack of action of guanine nucleotides (Nambi et al., 1996) and actions of receptor antagonists (Leite et al., 1994) . It is responsible for long-lasting actions of ET-1 and the development of long-term refractoriness. Recovery from refractoriness is variable from tissue to tissue. It is very slow in the cardiac muscle (Leite et al., 1994; Hilal-Dandan et al., 1997) but faster in the rat aorta (Marsault et al., 1993) and probably limited by the rate of externalization of newly formed or recycling receptors (Marsault et al., 1993) . Quasiirreversible binding may account for the fact that functional ET receptors serve as clearance receptors (Frelin and Gué-din, 1994 ). It imposes conditions in which autocrine actions (that is, vasodilating) of ET-1 should be favored over paracrine actions (that is, vasoconstricting) as observed in ET-1 ϩ/Ϫ mouse and provides a mechanism for the genesis of ET-1 induced vasospasms (Frelin and Guédin, 1994) . Finally, irreversible binding implies that ET-1 is more likely to contribute to long-term physiological or pathophysiological regulations than to short-term regulations (Hilal-Dandan et al., 1997) . Relieving the irreversibility of ET-1 binding is therefore important for a better understanding of the role of ET-1. It can be achieved using allosteric inhibitors of the receptors. This study shows that aspirin and SA are allosteric inhibitors of ETA receptors.
Salicylates Are Allosteric Modifiers of ETA Receptors. Salicylates reverse ET-1-induced contractions in isolated rat aortic rings and human mammary artery rings (Figs. 1 and 3) . These actions were observed in the absence of endothelium and for human tissues, in the presence of indomethacin. This, together with the observation (in the different assays that have been performed) that SA is slightly more potent than aspirin suggests that actions of salicylates are unlikely to be mediated by an inhibition of cyclooxygenase. Kinetic parameters of ET-1 binding to ETA receptors were determined from experiments such as those presented in Fig. 6 . Association kinetics were linearized according to pseudo first order processes to yield pseudo first order rate constants of association (kЈ a ). Second order rate constants of association (k a ) were determined from the relationship kЈ a ϭ k a ⅐ [ET-1] ϩ k d where k d was the first order rate constant of dissociation of ET-1 receptor complexes and [ET-1] was the concentration of labeled ET-1 used. The equilibrium dissociation constant (K d ) was determined from the relationship . This value is the mean of the four values determined in the presence of SA.
Allosteric Inhibition of Endothelin Receptors 801
Salicylates have anti-ET-1 actions in isolated vessels but also in isolated cells. They prevent the Ca 2ϩ mobilizing action of ET-1 in isolated endothelial cells but not those of neuromedin B or UTP (Fig. 4) . In the two preparations, salicylates shift the dose-response curves for the actions of ET-1 to larger concentrations, which may be suggestive of a competitive type of inhibition. This conclusion is supported by the results of binding experiments that show that SA prevents 125 I-ET-1 binding to recombinant ETA receptors by decreasing the apparent affinity of the receptors for ET-1 (Table 1 ). The mechanism of action of SA is more complex, however, for it promotes dissociation of 125 I-ET-1 receptor complexes (Figs. 6 and 7 ). These observations are strong indications that salicylates do not bind to the ET-1 site on ETA receptors and allosterically modify the interaction of ET-1 with its receptors. Whether salicylates act on the receptor itself, or on an associated protein, cannot be defined from our experiments.
Allosteric modulation of G protein-coupled receptors has already been described. It is best characterized with muscarinic receptors (Tucek and Proska, 1995) and has been studied to a limited extent with other receptors such as adenosine A1, ␣2-adrenergic, and D2 dopamine receptors (Bruns and Fergus, 1990; Hoare and Strange, 1998; Leppik et al., 1998 ). It was not described previously for ETA receptors. Allosteric modifiers of G protein-coupled receptors described so far are not structurally related to salicylates. Amiloride derivatives (benzamil and ethylisopropyl amiloride) that modify D2 dopamine receptors (Hoare and Strange, 1998) and ␣2-adrenergic receptors (Nunnari et al., 1987; Leppik et al., 1998) are inactive on ETA receptors (data not shown). We also show that concentrations of SA that inhibit ET-1 responses have no influence on neuromedin B and UTP responses in endothelial cells (Fig. 4) . These responses are mediated by neuromedin B-preferring bombesin receptors (Vigne et al., 1995) and P2Y 2 receptors , respectively. In addition, salicylates do not induce dissociation of ET-1 ETB receptor complexes (Fig. 8) . Thus, allosteric actions of salicylates are probably specific for ETA receptors.
Specificity of the Action of Salicylates. Actions of salicylates reported here were observed at large millimolar concentrations of the drugs. At such concentrations, weak 125 I-ET-1 (10 pM) and ETA receptor complexes were first allowed to form. SA was then added and dissociation of the complexes was followed. Concentrations of SA used were: 5 (F), 20 (OE), and 50 mM (f). Note that no unlabeled ET-1 was used in these experiments. 125 I-ET-1 and ETB receptor complexes were first allowed to form. Dissociation kinetics were then initiated by the addition of 100 nM unlabeled ET-1 in the absence (F) or the presence of 50 mM aspirin (E) or of 50 mM SA (Ⅺ). (Watala and Gwozdzinski, 1993; Balasubramanian et al., 1997) and to act as mild chaotropic agents. The following evidence suggests that actions of salicylates described here are not nonspecific: 1) SA selectively modifies the rate of dissociation of ET-1 ETA receptor complexes; 2) SA does not alter ETB receptors, neuromedin B-preferring bombesin receptors, and P2Y2 purinergic receptors; 3) Na benzoate did not induce dissociation of ET-1 receptor complexes; and 4) SA promotes dissociation of solubilized ET-1 receptor complexes (data not shown). The possibility that SA induced a degradation of free or receptor-bound ET-1 was also ruled out.
Relaxing Actions of Salicylates and Bosentan. The proposed mechanism of action of SA and aspirin can account (at least qualitatively) for the results obtained in functional assays. These are: 1) that fact that salicylates produced faster relaxations than bosentan, and 2) apparent competitive antagonism observed using intact vessels (Figs. 2 and 3 ) and endothelial cells (Fig. 4) .
It is also of interest to note that although salicylate-induced relaxations (Figs. 1 and 3) closely resemble salicylateinduced dissociations of 125 I-ET-1 receptor complexes (Fig.  7) , their time courses differ. Relaxations induced by salicylates are faster than salicylate-induced dissociation of ET-1 receptor complexes. A similar difference is observed with bosentan. The half-time for bosentan-induced relaxations (38 min) is much shorter than the half-life of ET-1 receptor complexes measured in the presence of bosentan (11.4 h). In other words, relaxations induced by bosentan or salicylates are observed under conditions in which most ET-1 remains bound onto receptors in experiments using membranes. One reason for this discrepancy could be that only receptors that recycle to the plasma membrane contribute to steady-state tension of isolated aortic strips (Marsault et al., 1991) . Receptor antagonists that do not induce dissociation of ET-1 receptor complexes relax arteries, for they compete with ET-1 for the occupancy of receptors (newly synthetized or recycling) that externalized to the plasma membrane. Under these conditions, the half-time for relaxations induced by receptor antagonists is not a measure of the half-time of ET-1 receptor complexes. It is a measure of the rate at which new receptors externalize to the plasma membrane (Marsault et al., 1991) . The same mechanism may account for salicylateinduced relaxations. One difference is, however, that although receptor antagonist can only compete with ET-1 for the occupancy of free receptors and cannot act if ET-1 has already bound to receptors, salicylates both prevent ET-1 binding and dissociate preformed complexes. This may be a reason why the half-time for salicylate-induced relaxations is faster than the half-time for bosentan-induced relaxations.
Pharmacological Implications. The most important observation of this study is that SA potentiates relaxing actions of bosentan (Fig. 10) . Several potent antagonists of ET receptors have been devised (Cheng et al., 1994) . They are usually potent in protocols in which animals are treated at the same time with ET-1 and with receptor antagonists, i.e., under conditions in which antagonists and ET-1 compete for the same free receptors. Antagonists are usually less potent when administered to prevent actions of endogenous, receptor-bound, ET-1. One alleged reason is that ET-1 plays a minor role in the physiopathological conditions that have been assessed. The observation that SA potentiates relaxing actions of bosentan (Fig. 10) suggests that actions of receptor antagonists may be limited by the slow rate of dissociation of ET-1 receptor complexes. Indeed, a competitive antagonist can only act if receptors are free from endogenous ET-1. Our results thus suggest that an association of salicylates and ETA receptor antagonists could be useful to evaluate the physiopathological role of ET-1 and may be of therapeutic interest is the treatment of ischemic heart disease.
Clinical Implications. Aspirin has clear beneficial actions in coronary heart disease. Recommended daily doses of aspirin for the prevention of myocardial infarction and vascular death in patients with coronary heart disease are about 200 mg. Larger doses may be needed in patients with cerebrovascular diseases (Patrono and Roth, 1996) . This study shows that millimolar concentrations of SA are needed to inhibit contractile actions of ET-1. Similar plasma concentrations of SA are only obtained with high anti-inflammatory doses of aspirin. This indicates that the mechanisms described in this article are unlikely to contribute to the beneficial actions of antiplatelet doses of aspirin in coronary heart disease.
